NEW YORK (TheStreet) -- Interexon (XON) - Get Intrexon Corporation Report shares are down by 14.68% to $49.21 in late morning trading on Tuesday, following the release of the synthetic biology company's 2015 second quarter earnings results yesterday.

The Germantown, MD-based company reported a net loss of $40.7 million, or a net loss of 25 cents per share on an adjusted basis. Revenue for the period was $44.9 million.

Analysts on average were expecting the company to report a net loss of 13 cents per share on revenue of $46.2 million.

"We continue satisfactorily to balance contemporary inputs to outputs while advancing a growing portfolio of programs that should provide significant and unburdened contribution to our bottom line," CEO Randal J. Kirk said in a statement.

"The scalability of our technology platforms and our organizational model are allowing us to grow our company rapidly across an ever diversifying array of great product candidates while we add important new talent to our team," Kirk added.

TheStreet Recommends

Separately, TheStreet Ratings team rates INTREXON CORP as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:

"We rate INTREXON CORP (XON) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow."

Image placeholder title

XON

data by

YCharts